Largest clinical development program of its class with more than 20 RCTs and 120,000-plus patients^7-27
Dosing regimens optimized for each therapeutic indication
Proven efficacy and safety profile across the most indications — NVAF, CAD, PAD, DVT/PE initial and extended treatment, and VTE prophylaxis in acutely ill medical patients and after hip/knee replacement surgery

ADULT DOSING Condition-specific dosing for your adult patients

ACCESS AND AFFORDABILITY Help your patients start and stay on therapy

Choose Savings/Support —

Janssen Select
Janssen CarePath
Formulary Finder

SAMPLES Request samples for your office today

EFFICACY Proven efficacy profile across 9 adult indications

Choose Indication —

NVAF
PAD
CAD
VTE Prophylaxis
DVT/PE Initial
DVT/PE Extended
DVT Prophylaxis

SAFETY Proven safety profile across 9 adult indications

Choose Indication —

NVAF
PAD
CAD
VTE Prophylaxis
DVT/PE Initial
DVT/PE Extended
DVT Prophylaxis

ADULT SWITCH AND MANAGEMENT Treatment considerations while switching to/from XARELTO^®

CAD = coronary artery disease; CV = cardiovascular; DVT = deep vein thrombosis; NVAF = nonvalvular atrial fibrillation; PAD = peripheral artery disease; PE = pulmonary embolism; RCTs = randomized clinical trials; VTE = venous thromboembolism.

References: 1. January CT, Wann LS, Alpert JS, et al; for the ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199-e267. Published correction appears in Circulation. 2014;130(23):e272-e274. 2. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135(12):e686-e725. 3. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126(25):e354-e471. 4. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2):e195S-e226S. 5. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693-4738. 6. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e278S-e325S. 7. Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-2775. 8. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510. 9. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9-19. 10. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891. 11. The EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-1297. 12. Cohen AT, Spiro TE, Büller HR, et al; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(6):513-523. 13. Cappato R, Ezekowitz MD, Klein AL, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35(47):3346-3355. 14. Cappato R, Marchlinski FE, Hohnloser SH, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015;36(28):1805-1811. 15. Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423-2434. 16. Eikelboom JW, Connolly SJ, Bosch J, et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319-1330. 17. Weitz JI, Lensing AWA, Prins MH, et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376(13):1211-1222. 18. Ohman EM, Roe MT, Steg G, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y₁₂ inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet. 2017;389(10081):1799-1808. 19. Peacock WF, Coleman CI, Diercks DB, et al. Emergency department discharge of pulmonary embolus patients. Acad Emerg Med. 2018;25(9):995-1003. 20. Hart RG, Sharma HM, Mundl H, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018;378(23):2191-2201. 21. Spyropoulos AC, Ageno W, Albers GW, et al; MARINER Investigators. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med. 2018;379(12):1118-1127. 22. Zannad F, Anker SD, Byra WM, et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med. 2018;379:1332-1342. 23. Dangas GD, Tijssen JGP, Wöhrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med. 2020;382:120-129. 24. Spyropoulos AC, Lipardi C, Xu J, et al. Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study. Clin Appl Thromb Hemost. 2019;25:1076029619886022. 25. Kakkar AK, Brenner B, Dahl OE, et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31-39. 26. Lassen MR, Ageno W, Borris LC, et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-2786.27. Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization [article and supplementary appendix]. N Engl J Med. 2020;382(21):1994-2004.

X

The 2023 ACC/AHA/ACCP/HRS Guideline Recommends XARELTO^® (rivaroxaban) as an Option for Eligible Patients With AF,* With No Age Limitations for Older Adults^¹

LEARN MORE

Use in Patients With Renal Impairment: Periodically assess renal function as clinically indicated (ie, more frequently in situations in which renal function may decline) and adjust therapy accordingly. Consider dose adjustment or discontinuation of XARELTO^® in patients who develop any renal failure while on XARELTO^®.²

Patients With End-Stage Renal Disease on Dialysis: Clinical efficacy and safety studies with XARELTO^® did not enroll patients with CrCl <30 mL/min or ESRD on dialysis. In patients with ESRD maintained on intermittent hemodialysis, administration of XARELTO^® 15 mg once daily will result in concentrations of rivaroxaban and pharmacodynamic activity similar to those observed in the ROCKET AF study. It is not known whether these concentrations will lead to similar stroke reduction and bleeding risk in patients with ESRD on dialysis, as was seen in ROCKET AF.²

*XARELTO^® is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. The use of XARELTO^® is not recommended in patients with prosthetic heart valves. While no longer using the "valvular" and "nonvalvular classifications of AF and concluding that those terms are obsolete, the 2023 Guideline for the Diagnosis and Management of Atrial Fibrillation notes that DOACs are currently recommended as first-line therapy over warfarin in patients with AF (except moderate to severe mitral stenosis or mechanical heart valve recipients).

ACC = American College of Cardiology; ACCP = American College of Clinical Pharmacy; AF = atrial fibrillation; AHA = American Heart Association; CrCl = creatinine clearance; DOAC = direct oral anticoagulant; ESRD = end-stage renal disease; HRS = Heart Rhythm Society; NVAF = nonvalvular atrial fibrillation.

References: 1. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024;83(1):109-279. 2. XARELTO^® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.

X

Do you want to leave XARELTOhcp.com?

By clicking on “Yes” below, you will leave XARELTOhcp.com.

Clicking on “Yes” below will take you to a website to which our site’s Privacy Policy does not apply. You are solely responsible for your interactions with that website. The links on XARELTOhcp.com are provided for informational purposes only and do not represent an endorsement, direct or implied, of the websites to which you will be directed.

YES NO

Dosing Across Indications
Legal Notice
Privacy Policy
Medical Information Center
Site Map

XARELTO^® is licensed from Bayer HealthCare AG, 51368 Leverkusen, Germany.

This site is published by Janssen Pharmaceuticals, Inc., which is solely responsible for its contents. This site is intended for use by healthcare professionals of the United States and Puerto Rico. Janssen Pharmaceuticals, Inc., recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States and Puerto Rico.

Third party trademarks used herein are trademarks of their respective owners.

Legal Notice | Privacy Policy | Medical Information Center

Do not sell my personal information

Last Updated 01/24

Loading Common Footer...

Updated AF Guideline

X

2023 ACC/AHA/ACCP/HRS Guideline Recommends XARELTO^® as an Option for Eligible Patients with AF,^* With No Age Limitations for Older Adults^¹

LEARN MORE

*XARELTO^® is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. The use of XARELTO^® is not recommended in patients with prosthetic heart valves. While no longer using the "valvular" and "nonvalvular" classifications of AF and concluding that those terms are obsolete, the 2023 Guideline for the Diagnosis and Management of Atrial Fibrillation notes that DOACs are currently recommended as first-line therapy over warfarin in patients with AF (except moderate to severe mitral stenosis or mechanical heart valve recipients).

ACC = American College of Cardiology; ACCP = American College of Clinical Pharmacy; AF = atrial fibrillation; AHA = American Heart Association; DOAC = direct oral anticoagulant; HRS = Heart Rhythm Society; NVAF = nonvalvular atrial fibrillation.

Reference: 1. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024;83(1):109-279.

Need Help?

XARELTO^® HCP and Staff Assistance

X

REQUEST A MEDICAL SCIENCE LIAISON (MSL) Schedule time with an MSL

Patients with thrombotic disease are complex.1-6

NVAFReduce stroke risk

PADReduce the risk of major thrombotic vascular events

CADReduce the risk of major CV events

VTE ProphylaxisAcutely ill medical patients

DVT/PEInitial treatment

DVT/PEExtended treatment

DVT ProphylaxisAfter hip/knee replacement surgery

Patients with thrombotic disease are complex.^1-6